-
RemeGen Ltd Reports 20.56% YOY Revenue Growth in H1 2023 Financial Results
•
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has released its financial report for the first half of 2023, recording revenues of RMB 422 million, an increase of 20.56% year-on-year (YOY). The company has also ramped up its research and development (R&D) costs to RMB 540 million, marking a 20.19% YOY…
-
Ascentage Pharma’s 2023 Interim Report: 49% YOY Revenue Growth and Market Expansion
•
China-based Ascentage Pharma (HKG: 6855) has released its 2023 interim financial report, revealing a 49% year-on-year (YOY) increase in revenues, reaching RMB 143 million (USD 19.6 million). This growth was primarily driven by product sales and commercial cooperation. Olverembatinib’s Market Performance and Upcoming ApprovalsAscentage Pharma’s first marketed product, olverembatinib, generated…
-
Ascletis Pharma Inc. Reports 21.7% Revenue Increase in H1 2023, Led by Ritonavir Sales
•
China-based Ascletis Pharma Inc., (HKG: 1672) has revealed revenues of RMB 46.51 million (USD 6.38 million) for the first half of 2023, marking a 21.7% increase year-on-year. The significant growth was primarily driven by Ritonavir, which contributed RMB 44.17 million, representing a substantial 6291.8% YOY increase. Ritonavir’s Impact and Pfizer…
-
New Horizon Health Ltd Reports 264.6% YOY Revenue Increase and First Recurring Profits
•
China-based New Horizon Health Ltd (HKG: 6606), a leading cancer diagnostics developer, has released its audited interim financial report for the period ended June 30, 2023. The company reported revenues of RMB 820 million (USD 112 million), marking a significant increase of 264.6% year-on-year (YOY). This period also saw the…
-
Jiangsu Hengrui Pharmaceuticals Reports 9.19% YOY Revenue Growth in H1 2023 Financial Report
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has released its financial report for the first half of 2023, reporting revenues of RMB 11.168 billion (USD 1.53 billion), marking a 9.19% increase year-on-year (YOY). The contribution from innovative drugs to this total was RMB 4.962 billion (USD 680 million). The company…
-
JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report
•
JD Healthcare, a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), has released its 2023 interim financial report, showing a 34% year-on-year (YOY) increase in total revenues to RMB 27.11 billion (USD 3.72 billion). Non-IFRS net profits surged by 101.2% to RMB 2.44 billion (USD 334.7 million), indicating strong financial…
-
Sinovac Biotech Reports H1 2023 Financials with Significant Sales Decline from COVID-19 Boom
•
Sinovac Biotech Ltd (NASDAQ: SVA) has published its financial results for the first half of 2023, revealing a significant drop in sales from the COVID-19 surge experienced in the same period last year. Sales have fallen to USD 140.4 million, down from USD 1.2 billion in the first six months…
-
Gracell Biotechnologies Reports Q2 2023 Financials, Highlights GC012F in Melanoma Treatment
•
Suzhou-based biotech company Gracell Biotechnologies Inc., (NASDAQ: GRCL) has reported its financial results for the second quarter of 2023. The report highlights the company’s core product, GC012F, which has shown excellent data in multiple melanoma (MM) studies, as a key focus of their strategy moving forward. Clinical Trials and Development…
-
Legend Biotech Corporation Reports Q2 and H1 2023 Financials with Increased Revenues and R&D Spending
•
Legend Biotech Corporation (NASDAQ: LEGN) has released its financial results for the second quarter and the first half of 2023. For the three months ended June 30, 2023, the company reported license revenue of USD 15.1 million, attributed to the achievement of a milestone during the quarter. Collaboration revenue reached…
-
Novo Nordisk’s H1 2023 Financials Show 30% YOY Growth Driven by GLP-1 Drugs and Obesity Sales
•
Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has announced its financial results for the first half of 2023, with GLP-1 drugs and obesity sales propelling a 30% year-on-year (YOY) increase in revenues to DKK 107.7 billion (USD 15.9 billion) in constant exchange rates. Diabetes and Obesity Care Business ExpansionThe…
-
Organon Reports Q2 2023 Revenue Growth, Driven by Women’s Health and Biosimilars
•
US-based Organon (NYSE: OGN) has reported its financial results for the second quarter of 2023, highlighting a robust performance with revenues increasing by 4% year-on-year (YOY) in constant exchange rate terms to USD 1.6 billion. The Women’s Health and Biosimilars units emerged as the strongest growth drivers for the company.…
-
Denali Therapeutics and Takeda Halt Development of Alzheimer’s Drug Candidate TAK-920/DNL919
•
US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial report that, in mutual agreement with development partner Takeda Pharmaceutical Co., Ltd (NYSE: TAK), the decision has been made to cease development of the Alzheimer’s drug candidate TAK-920/DNL919. This strategic decision was influenced by data…
-
Eli Lilly & Co. Reports 28% YOY Revenue Increase in Q2 2023 Financials
•
US pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) has released its financial results for the second quarter of 2023, revealing a robust 28% year-on-year (YOY) growth in revenues to USD 8.31 billion. This performance has surpassed expectations, prompting the company to upgrade its guidance for full-year revenues and profits.…
-
FibroGen’s Evrenzo Achieves Record Sales in China, Outlook for 2024 Remains Promising
•
US-based biopharmaceutical company FibroGen Inc., (NASDAQ: FGEN) has released its financial report for the second quarter of 2023, featuring record new highs for sales of the first-in-class HIF prolyl-hydroxylase inhibitor, Evrenzo (roxadustat), in China. Total net sales of Evrenzo in China, including through a joint venture with AstraZeneca, reached USD…
-
Bayer AG Reports Q2/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals
•
Germany-based multinational Bayer AG (ETR: BAYN) has released its financial report for the second quarter and first half of 2023, which indicates the group is facing difficulties due to the performance of its crop science and pharmaceutical business units. The China market, in particular, has been identified as a significant…
-
Zai Lab Ltd Reports Q2 2023 Financials with 53% YOY Product Revenue Growth
•
China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its financial results for the second quarter of 2023, along with recent product highlights and corporate updates. The company reported total product revenues of USD 68.9 million for the quarter, marking a 53% year-on-year (YOY) increase at constant exchange rates.…
-
Gilead Sciences Inc. Reports 5% YOY Revenue Increase in Q2 2023 Financials
•
US-based pharmaceutical major Gilead Sciences Inc., (NASDAQ: GILD) has released its financial results for the second quarter of 2023, reporting a 5% year-on-year (YOY) increase in global revenues to USD 6.6 billion. Excluding sales of the COVID-19 drug Veklury (remdesivir), revenues were up 11% YOY to USD 6.3 billion. HIV…
-
Amgen Inc. Reports 7% YOY Revenue Increase in Q2 2023 Financials
•
US-based biotechnology company Amgen Inc., (NASDAQ: AMGN) has released its financial results for the second quarter of 2023, reporting a total revenue increase of 7% year-on-year (YOY) in constant exchange rate terms, reaching USD 7 billion. Double-Digit Growth from Key TherapiesAmgen’s double-digit growth was driven by a range of therapies,…
-
BeiGene’s Q2 2023 Financial Report Highlights 81.8% YOY Product Revenue Growth
•
China-based biotech company BeiGene (SHA: 688235, HKG: 6160, NASDAQ: BGNE) has released its financial report for the second quarter of 2023, demonstrating strong year-on-year (YOY) growth of 81.8% in product revenues, reaching USD 553.7 million. Sales in China contributed USD 233.9 million, while the US market generated USD 223.5 million.…
-
Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials
•
Germany-based life sciences giant Siemens Healthineers AG (ETR: SHL) has released its financial results for the third quarter of its 2023 fiscal year, which ended on June 30. The company reported global revenues of EUR 5.2 billion (USD 5.6 billion), marking a 3.6% year-on-year (YOY) growth in constant exchange rate…
